Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | Phase 1 / Phase 2 | terminated | Nov 3, 2021 | National Health Research Institutes, Taiwan | The resolution of DSMB | Other (stated, no rule matched) |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 11, 2016 | Jazz Pharmaceuticals | This study was terminated due to a change in corporate priorities. The decision to terminate the… | Safety / toxicity |
| NCT03777410 | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | — | terminated | Dec 17, 2018 | Travera Inc | Insufficient pace of enrollment due to changes in MM SOC practices | Enrollment / accrual |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | Phase 2 | terminated | Oct 1, 2019 | Wake Forest University Health Sciences | PI left the institution and site decided not to continue the study | Investigator |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients… | Phase 2 | withdrawn | Jan 24, 2022 | Emory University | slow accrual | Enrollment / accrual |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Phase 1 | terminated | Feb 28, 2018 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With… | Phase 2 | terminated | Apr 20, 2020 | Emory University | Slow accrual | Enrollment / accrual |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Allogene Therapeutics | Terminated (Halted Prematurely) | Other (stated, no rule matched) |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 23, 2012 | Altor BioScience | Patient population did not benefit from single agent treatment. | Other (stated, no rule matched) |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Aug 30, 2019 | Takeda | Enrolment Challenges | Enrollment / accrual |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the… | Phase 1 | terminated | Jul 9, 2021 | Abdullah Khan | PI Decision | Other (stated, no rule matched) |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care…(ALUMMINATE) | Phase 3 | withdrawn | Jan 31, 2024 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | Early Phase 1 | terminated | Sep 17, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis…(BDI) | N/A | terminated | Dec 31, 2018 | Indiana University | Lack of accrual in a timely fashion | Enrollment / accrual |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute… | Phase 2 | withdrawn | Jan 18, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular… | Phase 1 / Phase 2 | terminated | Jan 25, 2021 | University of Chicago | funding | Funding |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | N/A | terminated | Jan 22, 2021 | Centre Hospitalier Henri Duffaut - Avignon | Heart rate measurement error | Other (stated, no rule matched) |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | Phase 2 | terminated | Aug 26, 2021 | Fundacion CRIS de Investigación para Vencer el Cáncer | closed because of low recruitment | Enrollment / accrual |
| NCT04242121 | The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow… | — | terminated | Jan 27, 2020 | Ivan S Moiseev | poor recruitment | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in… | Phase 2 | withdrawn | May 6, 2024 | National Cancer Institute (NCI) | No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior… | Enrollment / accrual |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4… | Phase 1 | terminated | Jul 21, 2017 | Dana-Farber Cancer Institute | Sponsor decision to end follow-up early | Sponsor / business decision |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | withdrawn | Jul 18, 2023 | Jonsson Comprehensive Cancer Center | The study was withdrawn before opening | Other (stated, no rule matched) |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or… | Phase 2 | terminated | May 29, 2020 | University of California, San Francisco | Slow enrollment and change in sponsor direction | Enrollment / accrual |
| NCT04685525 | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT | N/A | withdrawn | Dec 28, 2020 | Case Comprehensive Cancer Center | Administrative decision | Other (stated, no rule matched) |
| NCT00775502 | Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | Phase 1 | terminated | Oct 20, 2008 | Kyowa Kirin Co., Ltd. | lack of efficacy in Multiple myeloma | Efficacy / futility |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT02661022 | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and… | Phase 1 / Phase 2 | terminated | Jan 21, 2016 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT00893516 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | Phase 2 | terminated | May 6, 2009 | Emergent BioSolutions | Portfolio consolidation. | Sponsor / business decision |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT…(AHCT) | Early Phase 1 | withdrawn | Aug 19, 2021 | Koen van Besien | The original principal Investigator left the institution. | Investigator |
| NCT03288493 | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Phase 1 / Phase 2 | terminated | Sep 20, 2017 | Poseida Therapeutics, Inc. | Phase I portion of the study was completed. The phase II portion of the study was terminated early… | Other (stated, no rule matched) |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects… | Phase 2 | terminated | Feb 21, 2021 | Epizyme, Inc. | Decision to terminate EZH-1401 was solely due to company business decision. | Sponsor / business decision |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | Phase 1 | terminated | Oct 3, 2019 | Jorge J. Castillo, MD | Lack of efficacy | Efficacy / futility |
| NCT05711628 | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab)… | Phase 3 | withdrawn | Feb 3, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04083898 | Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma | Phase 1 | terminated | Sep 10, 2019 | Washington University School of Medicine | Decision made to not move forward with Phase II portion of trial | Other (stated, no rule matched) |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | Phase 1 / Phase 2 | withdrawn | Nov 14, 2022 | Zhujiang Hospital | The company failed to provide corresponding CART services. | Sponsor / business decision |
| NCT03473496 | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma(MM) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | After CAR-T treatment, the benefit is not significant, and it is difficult to enroll. | Enrollment / accrual |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | Phase 2 | terminated | May 21, 2015 | Swiss Cancer Institute | The premature termination is based on the decision by the SAKK board on November 14, 2020 due to… | Funding |
| NCT02700841 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | Phase 2 | terminated | Mar 7, 2016 | University of Nebraska | Study terminated prematurely due to poor recruitment. | Enrollment / accrual |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | Phase 2 | withdrawn | Jun 12, 2019 | Ludwig-Maximilians - University of Munich | Lack of potential study subjects due to a change of standard of care treatment outside of clinical… | Other (stated, no rule matched) |
| NCT06160609 | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40… | Phase 1 / Phase 2 | terminated | Dec 7, 2023 | GlaxoSmithKline | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With… | Phase 1 / Phase 2 | terminated | Aug 12, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04548700 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and… | Phase 1 | terminated | Sep 14, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT06104878 | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With… | — | withdrawn | Oct 27, 2023 | Takeda | Company decision after projects re-evaluation, taken before the study initiation | Sponsor / business decision |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 8, 2024source: clinicaltrials